Canaccord raised the firm’s price target on Intra-Cellular to $113 from $107 and keeps a Buy rating on the shares. The target increase is the result of remarkably consistent Phase 3 data for its MDD treatment and means it’s on to a filing for luma in major depressive disorder. Upsie potential exists as the approval is now more when, not if.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular price target raised to $92 from $91 at BofA
- Intra-Cellular announces results for lumateperone as adjunctive therapy in MDD
- Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
- Intra-Cellular price target raised to $78 from $75 at JPMorgan
- Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference